Protalix BioTherapeutics' Quiet Surge in Rare Disease Therapies Protalix BioTherapeutics, Inc. has been flying under the radar, but its recent financials suggest a company on the cusp of significant growth.
The company's strong first half performance and growing pipeline indicate that it is poised to make a splash in the rare renal disease market.
One key factor driving revenue growth for Protalix is the increasing demand for Elfabrio, its flagship therapy for Fabry disease.